Melissa Johnson
MD
Director of Lung Cancer Research Program
👥Biography 个人简介
Dr. Melissa Johnson is a thoracic oncologist and prolific clinical trialist who has led studies of telisotuzumab vedotin (ABBV-399), an ADC targeting MET-overexpressing NSCLC. She is a principal investigator in LUMINOSITY and other trials evaluating MET expression by IHC as a biomarker for telisotuzumab selection. Her broad clinical trial portfolio encompasses multiple novel thoracic oncology therapeutics.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Melissa Johnson 的研究动态
Follow Melissa Johnson's research updates
留下邮箱，当我们发布与 Melissa Johnson（Sarah Cannon Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment